Prevention of Cardiac Allograft Vasculopathy With Certican® (Everolimus): The Stanford University Experience Within the Certican Phase III Clinical Trial
- 30 April 2005
- journal article
- case report
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (4) , S191-S195
- https://doi.org/10.1016/j.healun.2005.01.012
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- The Role of Viruses in Cardiac Allograft VasculopathyAmerican Journal of Transplantation, 2004
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsNew England Journal of Medicine, 2003
- The registry of the international society for heart and lung transplantation: twentieth official adult heart transplant report—2003The Journal of Heart and Lung Transplantation, 2003
- The role of certican (everolimus, rad) in the many pathways of chronic rejectionTransplantation Proceedings, 2001
- INCIDENCE, PROGRESSION AND FUNCTIONAL SIGNIFICANCE OF CARDIAC ALLOGRAFT VASCULOPATHY AFTER HEART TRANSPLANTATION1Transplantation, 2000
- SDZ RAD inhibits cold ischemia-induced vascular remodelingTransplantation Proceedings, 1999
- Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic modelTransplantation Proceedings, 1998
- A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1Transplantation, 1998